Several drug companies and advocacy organizations express support for FDA’s draft guidance on developing new drugs to treat early-stage Alzheimer’s disease.
Attorney Kurt Karst says a DC appeals court decision may help those seeking documents from FDA under the Freedom of Information Act to force the agency to move more quickly.
An unidentified company asks FDA not to publish a Warning Letter it received until the firm has exhausted its appeals and resolves other issues relating to contents of the letter.